57 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
%. Generally, we are responsible for the withholding of such dividend withholding tax at source; the dividend withholding tax is for the account … is responsible for our management, strategy, policy and operations. The executive directors manage our day-to-day business and operations and implement our
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
Proceeds Confirmation is given, the Net Proceeds will be delivered to the Company promptly following the Settlement Date). The Agent shall be responsible
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash.
Healthcare providers and/or their designee are responsible
6-K
EX-99.1
IFRX
InflaRx N.V.
21 May 24
Report of Foreign Private Issuer
4:15pm
, supraventricular tachycardia, constipation, and rash.
Healthcare providers and/or their designee are responsible for mandatory FDA MedWatch reporting of all
6-K
EX-99.1
IFRX
InflaRx N.V.
4 Apr 24
Current report (foreign)
4:01pm
served as the Chief Business Officer of Achillion Pharmaceuticals, Inc., where he was responsible for corporate and portfolio strategy, business
6-K
EX-99.1
0rfhphfe1341eftpy4xr
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
424B5
snbq37 9a70
12 Jul 23
Prospectus supplement for primary offering
12:00am
UPLOAD
2f6oga22qp3
6 Jul 23
Letter from SEC
12:00am
F-3
EX-4.3
bzfm613omxx452mb
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.2
n337ep
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
ipv46ua
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
6ewcwgmq7nnd4tury2vi
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
6-K
EX-99.1
tsz bcy3e3vsti
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-1.1
5mw2o
13 Apr 23
Current report (foreign)
4:01pm
424B5
426qrhw5irqsgji8sdyd
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
tlbgs4er3kii5nn6 pr
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
gdgey
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm